SAN DIEGO, November 2026 – BlackLight Surgical CEO Frank Cheng was invited to present at the MedTech Strategist Innovation Summit San Diego 2026. The summit brings together medical technology innovators, investors, and industry leaders to showcase emerging companies and discuss how breakthrough technologies reach patients.
In his presentation, Mr. Cheng introduced BlackLight’s cancer detection technology, developed in collaboration with Cedars-Sinai Medical Center and awarded FDA Breakthrough Designation. The technology visualizes cancer tissue in real time in the operating room, with high precision and without the need to inject dyes or drugs. Helping surgeons see cancer more clearly during an operation can support more complete tumor removal and reduce the need for repeat procedures.
“It was a privilege to share BlackLight’s story with this community of innovators and investors,” said Frank Cheng, CEO of BlackLight Surgical. “Surgeons need better ways to see cancer while they are operating, and we believe our technology can deliver that without adding a dye or a drug to the procedure. The conversations at the summit reinforced the urgency of bringing it to patients.”
BlackLight Surgical continues to advance its technology toward the clinic and welcomes conversations with clinical, industry, and investment partners.
About BlackLight Surgical
BlackLight Surgical is a pioneer in intraoperative cancer detection technologies for interventional oncology. Developed in collaboration with Cedars-Sinai Medical Center, BlackLight’s system uses dye-free fluorescence imaging to identify cancerous tissue with high precision. The technology has received FDA Breakthrough Device designation. BlackLight’s mission is to help surgeons see cancer clearly during surgery so that patients can be treated successfully with a single operation. For more information, visit bls.life.